ImmunityBio (IBRX)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$0.27 (-5.53%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of ImmunityBio (IBRX)
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.

Key Insights

Critical company metrics and information
  • Share Price

    $4.68
  • Market Cap

    $3.26 Billion
  • Total Outstanding Shares

    696.83 Million Shares
  • Total Employees

    672
  • Dividend

    No dividend
  • IPO Date

    March 10, 2021
  • SIC Description

    Biological Products, (no Disgnostic Substances)
  • Homepage

    https://www.immunitybio.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities, Continuing$-19.83 Million
Net Cash Flow From Financing Activities$375.24 Million
Net Cash Flow, Continuing$-65.95 Million
Net Cash Flow From Investing Activities$-19.83 Million
Net Cash Flow From Financing Activities, Continuing$375.24 Million
Net Cash Flow$-65.95 Million
Net Cash Flow From Operating Activities, Continuing$-421.36 Million
Net Cash Flow From Operating Activities$-421.36 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Income/Loss From Continuing Operations After Tax$-587.88 Million
Nonoperating Income/Loss$-227.75 Million
Income/Loss From Equity Method Investments$0.00
Preferred Stock Dividends And Other Adjustments$0.00
Selling, General, and Administrative Expenses$160.16 Million
Research and Development$206.46 Million
Diluted Average Shares$742.58 Million
Diluted Earnings Per Share$0.91
Benefits Costs and Expenses$595.25 Million
Net Income/Loss Attributable To Noncontrolling Interest$86000.00
Net Income/Loss Available To Common Stockholders, Basic$-587.79 Million
Income Tax Expense/Benefit$40000.00
Basic Earnings Per Share$0.90
Net Income/Loss Attributable To Parent$-587.79 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Net Income/Loss$-587.88 Million
Operating Expenses$367.50 Million
Basic Average Shares$738.90 Million
Operating Income/Loss$-360.17 Million
Income/Loss From Continuing Operations Before Tax$-587.92 Million
Revenues$7.33 Million
Costs And Expenses$595.25 Million
Interest Expense, Operating$120.72 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Liabilities$1.11 Billion
Fixed Assets$139.28 Million
Equity Attributable To Noncontrolling Interest$986000.00
Current Liabilities$60.96 Million
Equity Attributable To Parent$-745.15 Million
Other Non-current Assets$62.13 Million
Liabilities And Equity$364.57 Million
Inventory$1.96 Million
Current Assets$163.15 Million
Assets$364.57 Million
Noncurrent Liabilities$1.05 Billion
Other Current Assets$161.19 Million
Noncurrent Assets$201.42 Million
Equity$-744.16 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.